Next-Generation ADCs: Advancing Targeted Cancer Therapy

2:45 pm - Tuesday 9th March 2027

  • Developing next-generation ADCs designed to overcome resistance to current ADC therapies
  • Leveraging innovative payloads and advanced conjugation strategies to enhance efficacy and expand the therapeutic window
  • Translating novel ADC technologies into differentiated therapies for patients with high unmet need

Speakers:

Chief Operating Officer
Adcytherix